MedTrace Logo

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

NCT00588835 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-11-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether aprepitant can be used in the Cisplatin - Etoposide chemotherapeutic regimen.

Conditions

  • Tumor

Interventions

DRUG

aprepitant

125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.

DRUG

Dexamethasone and Ondansetron during CE-treatment

Standard anti-emetic regimen during CE treatment

Sponsors & Collaborators

Principal Investigators

  • David M. Burger, PharmD PhD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00588835 on ClinicalTrials.gov